The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2025 | Exciting advances in the lymphoma treatment landscape: BTK degraders
John Kuruvilla, MD, FRCPC, Princess Margaret Cancer Centre, Toronto, Canada, briefly discusses promising novel agents being explored in lymphoma, drawing focus on BTK degraders, which have demonstrated feasibility, safety, and efficacy in early studies. This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
It’s been a really exciting time in lymphoma recently with the development of many new drugs. In particular, we’ve been able to see the development of immunotherapy, which has really changed practice, but increasingly we need to find other new alternatives and new mechanisms of action. So what we’ve seen of interest at the most recent meetings in the summer, in particular, have been a class of drugs called degraders, which are now taking targets that we already know about such as BCL2 or BTK and targeting these oncogenic pathways in a different way...
It’s been a really exciting time in lymphoma recently with the development of many new drugs. In particular, we’ve been able to see the development of immunotherapy, which has really changed practice, but increasingly we need to find other new alternatives and new mechanisms of action. So what we’ve seen of interest at the most recent meetings in the summer, in particular, have been a class of drugs called degraders, which are now taking targets that we already know about such as BCL2 or BTK and targeting these oncogenic pathways in a different way. The theory is that we’ll be able to avoid some of the mutational lead resistance that we may see with these traditional drugs but with degraders we may be able to optimize outcome. The studies so far really speak to feasibility, safety, some early signs of efficacy and we look forward to seeing these drugs moving forward in development.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video
Read more...
